Publications by authors named "L Rihova"
Minimal residual disease (MRD) is one of the most important prognostic factors in multiple myeloma (MM) and a valid surrogate for progression-free survival (PFS) and overall survival (OS). Recently, MRD negativity was approved as an early clinical endpoint for accelerated drug approval in MM. Nevertheless, there is limited evidence of MRD utility in real-world setting.
View Article and Find Full Text PDFJAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.
Clin Hemorheol Microcirc
October 2023
The clinical course of essential thrombocythemia (ET) is complicated with thrombosis which significantly impacts patients' mortality. Studies have identified JAK2V617F mutation as an independent risk factor for thrombosis. Circulating extracellular vesicles (EVs) were evaluated in several studies regarding myeloproliferative neoplasms and thrombosis as potential biomarkers.
View Article and Find Full Text PDFExtramedullary multiple myeloma (EMD) is an aggressive disease; malignant plasma cells lose their dependence in the bone marrow microenvironment and migrate into tissues. EMD is a negative prognostic factor of survival. Using flow cytometry and next-generation sequencing, we aimed to identify antigens and microRNAs (miRNAs) involved in EMD pathogenesis.
View Article and Find Full Text PDFArticle Synopsis
- The study examines primary plasma cell leukemia (PCL), previously defined by ≥ 20% circulating plasma cells, now suggested to be diagnosed by a lower threshold of ≥ 2% CTCs, indicating it might just be ultra-high-risk multiple myeloma (MM).
- Researchers measured CTC levels in 395 newly diagnosed transplant-ineligible MM patients and found that those with 2%-20% CTCs had poorer survival outcomes compared to those with < 2%, emphasizing the clinical relevance of a lower cutoff.
- The findings support using the 2% cutoff as a potential biomarker for identifying hidden primary PCL and advocate for flow cytometry assessment during MM diagnosis to improve patient stratification and treatment decisions.
Background/aim: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN).
Patients And Methods: In a cohort of 206 patients with MPN, MPs' procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while platelet- and erythrocyte-MPs were enumerated by flow cytometry in 558 samples.
Results: MPN patients had higher MP levels than the control group.